Summary.-Spleen-cell sensitivity to encephalitogenic factor (EF) was measured with the macrophage migration inhibition (MMI) test over a period of time in hamsters inoculated with SV40-transformed tumour cells and in rats treated with 4-dimethylamino -3'-methylazobenzene.
PONSE to encephalitogenic factor (EF) has been demonstrated in malignant neoplastic disease with both the macrophage migration inhibition (MMI) test (Light, Preece and Waldron, 1975; Shelton, Potter and Carr, 1975; Flavell and Potter, 1978) and the macrophage electrophoretic mobility (MEM) test (Field and Caspary, 1970; Caspary and Field. 1971; Pritchard et al., 1973; Goldstone, Kerr and Irvine, 1973) . However, it is not clear at which point in the neoplastic process such sensitivity becomes apparent and this remains one of the outstanding problems related to the delayed hypersensitivity response to this antigen in malignant disease. Data from Field, Caspary and Shepherd (1972) and Pritchard et al. (1976) suggest that sensitivity manifests itself many years before the appearance of clinicallv detectable tumour. An early lymphocyte response to EF during tumour development was also reported by Singer et al. (1975) and Porzsolt, Muhlberger and Ax (1975) , who detected sensitization to EF in a large proportion of women with cervical dysplasia.
Sensitivity to EF has also been reported in a number of animal tumour systems. Thus, Shelton et al. (1975) Encephalitogenic factor.-EF was prepared from human brain as previously described (Flavell and Potter, 1978) . Human EF made by this method has been shown to cross-react immunologically with hamster or rat EF as determined by skin testing in guinea-pigs immunized previously with human EF in Freund's complete adjuvant.
Macrophage migration inhibition (MMI) test
Spleen-cell preparation.-Hamster or rat spleens were removed aseptically and washed briefly in ice-cold Medium 199. Hamster spleens within each group were pooled, whilst rat spleens were processed individually. The spleens were briefly homogenized in Medium 199 and the fragments filtered through a double layer of sterile muslin. Erythrocytes were removed by flash lysis with distilled water for 20 sec followed by the addition of an equal amount of 0-3Ml NaCl solution. The cell suspension was washed x 3 in Medium 199 containing 10% heat-inactivated foetal calf serum, and the concentration of cells adjusted to 2-0 x 106 viable cells/ml.
Peritoneal-exudate cell preparation.-Peritoneal-exudate cells (PEC) were induced in Hartley guinea-pigs (200-400 g) by i.p. stimulation with 10 ml of sterile liquid paraffin (Hills Pharmaceuticals Ltd., Burnley). The PEC were collected and processed as described previously (Rees and Potter, 1973 (Flavell and Potter, 1978 inhibition. Blood specimens collected from rats by cardiac puncture were allowed to clot at room temperature for 1 h and then centrifuged at 1500 g for 10 min. The serum was harvested and heat-inactivated at 56°C for 30 min. The effects of autologous serum upon EF-mediated migration inhibition were investigated by including serum in duplicate sets of wells at a concentration of 10% with and without EF. Histological examination of rat livers.-Rat livers were fixed in alcoholic formalin, and 6-8 representative portions were taken for processing into paraffin wax. Sections were cut and stained with haematoxylin and eosin and also for reticulin. Sections were examined by light microscopy without knowledge of the results of the MMI test, and pathological features wNere recorded using a simple scoring system. After a period of weeks, the sections were reassessed without reference to the first results. Finally, sections from animals were divided into 2 groups: from animals showing significant migration with EF and from those which did not. These 2 groups of sections were then presented unlabelled to a second pathologist to examine factors that might be specific to either group. Following the first and second assessments, the rats were assigned to 4 groups: Group 0, very little or no change; Group 1, proliferative changes including cholangiofibrosis; Group 2, dysplasia of portal-tract epithelial cells; Group 3, cholangiocarcinoma.
RESULTS
Sensitivity to EF in SV40-tumour-bearing Shelton et al. (1975) have shown that hamsters bearing SV40-induced tumours show a response to EF with the MMI test 10 days after tumour implantation, and Pasternak et al. (1.976) have shown a response to EF in mice bearing tumours of different aetiology. However, no studv has been made in an animal model system to investigate the point during tumour progression at which sensitivity to EF becomes apparent. In humans, the studies of Singer et al. (1975) and Porzsolt et al. (1975) have shown that a high proportion of women with dysplastic lesions of the cervix show a lymphocyte response to EF with the MMI and MEM tests, respectively. These results suggest that a lymphocyte response to EF occurs early in tumour development.
The results of the present study have shown that hamsters bearing transplanted SV40 tumours show a spleen-cell response to EF 21 days after implantation of tumour cells. Thus, spleen cells from animals receiving tumour-cell inoculum of 105 cells gave MMI with EF at a significance level of P<0 00] 21 days after implantation. Many workers accept P< 0 05 as indicative of significant migration inhibition, but from our stringent statistical analysis spleen cells from animals receiving 10 or 103 SV40-tumour cells, which gave MMI with EF at a significance level of P< 005 21 days after implantation, cannot be considered as significant. It might therefore be concluded that the immune response to EF in animals bearing SV40 tumours takes up to 21 days to develop, and that its development to a highly significant level is dependent upon the size of tumour cell inoculum.
The observations made in rats with 3'-Me-DAB-induced hepatic lesions suggest that a cell-mediated immune response to EF occurs before the appearance of a carcinoma. The gross and microscopic appearances of the rat livers were similar to those described by other workers using 3'-Me-DAB and related carcinogens (Orr, 1940; Richardson and Borsos-Nachtnebel, 1951; Price, Miller and Miller, 1959; (Goldfarb, 1973) and, in particular the finding of cholangiocarcinoma and not hepatocellular carcinoma by Reddy, Buschmann and Chomet (1977) . These workers have applied a variety of interpretations to the spectrum of changes seen, and the difficulties of classification are reflected in this study. However, all authors agree that there is some form of identifiable pre-neoplastic lesion. Gold- Whilst the observations of the present study suggest that a cell-mediated immune response to EF occurs in association with dysplastic lesions, it is possible that due to inadequate sampling small foci of mnalignant change were not discovered, but this seems unlikely in every case. The findings that rats with dysplastic hepatic lesions show a response to EF are in agreement with the observations of other workers, in which lymphocyte sensitivity to EF was found in women with dysplastic cervical lesions (Singer et al., 1975; Porzsolt et al., 1975) . It is not possible to say whether the spleen-cell response to EF seen in the rats with dysplastic hepatic lesions was due to the appearance of neoantigen(s) on the dysplastic epithelial cell surface immunologically crossreactive with EF (Caspary and Field, 1971) or to tissue damage by the carcinogen or neoplasm resulting in the release or normally sequestered tissue components which subsequently immunize the host (Mitchell, 1973) . Indeed, the appearance of a delayed hypersensitivity response to EF in some animals or humans bearing potentially malignant dysplastic lesions might indicate the malignant potential of these lesions.
Serum abrogation of EF-mediated MMI was seen early in hepatocarcinogenesis in the one sensitized animal with proliferative changes and cholangiofibrosis and in all 7 sensitized animals with dysplastic hepatic lesions. Of the 5 sensitized rats with cholangiocarcinomas, 4 showed serum abrogation of EF-mediated MMI. Flavell and Potter (1978) have demonstrated the abrogation of EF-mediated MMI in patients with cancer, and have shown that this abrogatory effect is independent of the extent of disease, and operates in the homologous situation between individuals with different tumour types. The observations made in the present study suggest that the serum-blocking effect observed is different from those seen by workers using tumour-specific antigens or whole viable tumour cells in microcytotoxicity assays, where serum blocking activity correlates well with the extent of the disease (Currie, 1973; Bray and Holt, 1975) . The nature and significance of the serum effect seen in the present study is unknown; it is possibly due to the release or production of immunoregulatory substances during tissue damage, with the role of modulating the immune response and thus preventing the occurrence of an autoimmune reaction to released normal tissue components. In support of this are the findings of Bernard and Lamoureux (1975) who have demonstrated that the aX2 macroglobulin component of serum suppiesses the ability of EF to induce allergic encephalomyelitis in guinea-pigs.
